Lautt W Wayne, Macedo M Paula, Sadri Parissa, Legare Dallas J, Reid Maria A G, Guarino Maria P
Department of Pharmacology & Therapeutics, University of Manitoba, Winnipeg, Manitoba, Canada.
Proc West Pharmacol Soc. 2004;47:30-2.
Insulin action is approximately doubled following a meal. The mechanism of postprandial insulin sensitization is dependent on hepatic parasympathetic nerves regulated by the prandial status. The nerves provide a permissive signal to the liver that allows insulin to cause the release of a putative hepatic insulin sensitizing substance (HISS) that selectively stimulates glucose uptake into skeletal muscle but not liver or adipose tissue. The parasympathetic signal has several steps identified in the regulatory pathway; acetylcholine acts on muscarinic receptors leading to activation of nitric oxide synthase and generation of HISS. The meal-induced insulin (MIS) sensitization requires hepatic GSH, which decreases with fasting and several disease states. Interfering with the MIS process results in severe insulin resistance with the response to insulin being reduced by approximately 50% to levels seen in the fasted state. A wide range of conditions have been shown to be associated with insulin resistance attributed to lack of the MIS process including insulin resistance; in chronic liver disease produced by chemical damage or bile duct ligation, hepatic denervation, sucrose fed rats, aging, spontaneously hypertensive rats, fetal alcohol exposed adult offspring, spontaneously insulin resistant rats, animals with pharmacological blockade of hepatic muscarinic receptors, NO synthase, cyclooxygenase, hepatic cGMP, and hepatic GSH levels. Pharmaceutical reversal of insulin resistance has been shown in several models using a variety of approaches including mimicking or potentiating the parasympathetic signal using cholinergic agonists, NO donors, cholinesterase antagonists, phosphodiesterase antagonists, and replenishment of hepatic GSH levels. These compounds are being evaluated for therapeutic application by our international academic/industry collaborative team. The MIS process has now been demonstrated in mice, rats, guinea pigs, cats, dogs, and humans, and has been demonstrated by independent laboratories.
进食后胰岛素作用增强约一倍。餐后胰岛素敏感性增强的机制依赖于受进食状态调节的肝脏副交感神经。这些神经向肝脏提供一种允许信号,使胰岛素能够促使一种假定的肝脏胰岛素增敏物质(HISS)释放,该物质选择性地刺激骨骼肌摄取葡萄糖,而不刺激肝脏或脂肪组织摄取葡萄糖。在调节途径中已确定副交感神经信号有几个步骤;乙酰胆碱作用于毒蕈碱受体,导致一氧化氮合酶激活并生成HISS。进食诱导的胰岛素(MIS)敏感性需要肝脏谷胱甘肽(GSH),其在禁食和几种疾病状态下会减少。干扰MIS过程会导致严重的胰岛素抵抗,对胰岛素的反应降低约50%,降至禁食状态下的水平。已证明多种情况与因缺乏MIS过程导致的胰岛素抵抗有关,包括胰岛素抵抗;在化学损伤或胆管结扎所致的慢性肝病、肝脏去神经支配、喂食蔗糖的大鼠、衰老、自发性高血压大鼠、胎儿酒精暴露的成年后代、自发性胰岛素抵抗大鼠、用药物阻断肝脏毒蕈碱受体、一氧化氮合酶、环氧化酶、肝脏环鸟苷酸(cGMP)和肝脏GSH水平的动物中。在几种模型中已显示,使用多种方法(包括使用胆碱能激动剂、一氧化氮供体、胆碱酯酶拮抗剂、磷酸二酯酶拮抗剂模拟或增强副交感神经信号以及补充肝脏GSH水平)可实现胰岛素抵抗的药物逆转。我们的国际学术/产业合作团队正在评估这些化合物的治疗应用。MIS过程现已在小鼠、大鼠、豚鼠、猫、狗和人类中得到证实,并且已被独立实验室证实。